Erste Group Bank Lowers Earnings Estimates for Novartis

Key Points

• Erste Group Bank lowered Novartis’ FY2026 EPS estimate to $8.95 from $9.01, though the revised forecast remains above the analyst consensus of $8.84.
• Novartis holds an overall “Hold” consensus rating, with seven Buy, seven Hold, and two Sell ratings; the average price target is $141.20.
• Novartis reported quarterly EPS of $2.41 on $14.95 billion in revenue, while its shares recently opened at $153.75 and have traded between $121.57 and $170.46 over the past year.

Novartis AG (NYSE:NVS - Free Report) - Research analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for shares of Novartis in a note issued to investors on Thursday, August 27th. Erste Group Bank analyst H. Engel now expects that the company will earn $8.95 per share for the year, down from their previous estimate of $9.01. The consensus estimate for Novartis' current full-year earnings is $8.84 per share.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a research report on Friday, July 24th. Citigroup reaffirmed a "buy" rating on shares of Novartis in a research report on Wednesday, July 22nd. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $141.20.

Novartis Stock Performance

NVS stock opened at $153.75 on Monday. Novartis has a 1-year low of $121.57 and a 1-year high of $170.46. The business has a 50-day moving average price of $155.07 and a 200 day moving average price of $153.76. The company has a market capitalization of $293.38 billion, a P/E ratio of 23.19, a PEG ratio of 2.64 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NVS. Cornerstone Financial Management LLC boosted its holdings in Novartis by 12.0% in the second quarter. Cornerstone Financial Management LLC now owns 980 shares of the company's stock worth $154,000 after acquiring an additional 105 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Novartis by 1.2% during the second quarter. HighTower Advisors LLC now owns 267,821 shares of the company's stock valued at $41,973,000 after acquiring an additional 3,182 shares in the last quarter. Tanager Wealth Management LLP acquired a new position in shares of Novartis during the second quarter valued at about $201,000. Ameritas Advisory Services LLC raised its position in shares of Novartis by 94.4% in the 2nd quarter. Ameritas Advisory Services LLC now owns 4,647 shares of the company's stock valued at $728,000 after purchasing an additional 2,256 shares during the last quarter. Finally, Kintra Wealth LLC raised its position in shares of Novartis by 48.7% in the 2nd quarter. Kintra Wealth LLC now owns 5,118 shares of the company's stock valued at $776,000 after purchasing an additional 1,677 shares during the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source